The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety, tolerability, and preliminary efficacy of tinodasertib as a monotherapy or in combination with pembrolizumab or irinotecan in metastatic colorectal cancer: Interim results from a phase II open-label, dose-finding, run-in and cohort expansion study.
 
Marco Matos
No Relationships to Disclose
 
George Kannourakis
No Relationships to Disclose
 
Morteza Aghmesheh
No Relationships to Disclose
 
Shehara Mendis
Speakers' Bureau - Antegene; Servier/Pfizer; Specialised Therapeutics
 
Kate Mahon
No Relationships to Disclose
 
Harish Dave
Employment - AUM Biosciences
Leadership - AUM Biosciences
Stock and Other Ownership Interests - AUM Biosciences
 
Prajak Barde
Employment - AUM Biosciences Pte Ltd
 
Anke Schwedat
Employment - AUM Biosciences Pty Ltd
Research Funding - AUM Biosciences Pty Ltd
 
John Patava
Employment - AUM Biosciences Pty Ltd
Leadership - AUM Biosciences Pty Ltd
Stock and Other Ownership Interests - AUM Biosciences Pty Ltd
Research Funding - AUM Biosciences Pty Ltd